The US Food and Drug Administration has expanded the use of Eli Lilly’s tirzepatide, or Mounjaro, to include lowering the risk of major cardiovascular events in adults with high-risk type 2 diabetes, based on a significant clinical trial demonstrating its cardiovascular benefits.
The US Food and Drug Administration has approved tirzepatide, sold as Mounjaro, for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk, Eli Lilly said in a statement. The expanded indication gives the medicine a role beyond glucose control and weight management, placing heart protection alongside its established metabolic benefits.
The approval is based on SURPASS-CVOT, a large cardiovascular outcomes trial that compared tirzepatide with dulaglutide, or Trulicity. According to the company and cardiology reporting on the study, tirzepatide met the standard for non-inferiority and was associated with an 8% lower rate of cardiovascular death, heart attack or stroke. The trial enrolled more than 13,000 people across 30 countries and followed them for roughly four years, making it the first head-to-head outcomes study of two incretin-based medicines rather than a drug against placebo.
Eli Lilly said the result is significant because cardiovascular risk in type 2 diabetes is often addressed later than blood sugar control. Duke University endocrinologist David A. D’Alessio, a study co-author, said in the company’s news release that heart health should be considered throughout treatment, not only after a major event. A post hoc analysis published in JAMA Cardiology also found tirzepatide was linked with a lower rate of a broader cardiorenal composite outcome than dulaglutide, although gastrointestinal side effects were more common.
The decision also adds to a broader body of evidence suggesting that GLP-1-based medicines can reduce cardiovascular risk. A meta-analysis in the American Journal of Preventive Cardiology found a 14% reduction in major adverse cardiovascular events and a 13% reduction in all-cause mortality across placebo-controlled trials of GLP-1 receptor agonists, with benefits also seen in kidney outcomes. In practice, the approval is likely to reinforce the role of pharmacists and other clinicians in helping patients with diabetes and cardiovascular disease stay on therapy, monitor side effects and manage adherence.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
